Update on HIV/AIDS
HIV-1 is a more dangerous virus than HIV-2: AIDS developed in 54% of people with HIV-1 and 43% of people with HIV-2. After eight years, half of those with HIV-1 had died. In comparison, after 15 years, half of those with HIV-2 had died.
The Food and Drug Administration (FDA) recently announced the approval of Dovato, the first complete two-drug HIV treatment regimen for people who previously have not been on antiretroviral therapy. Why is Dovato significant? It offers the potential for these people to take their two-drug regimen in one single tablet. PrEP:
Truvada is a brand-name prescription medication that's used for treating HIV infection. It's also used for preventing HIV infection in people who have a high risk of getting HIV. This use, in which the treatment is given before the person may be exposed to HIV, is called pre-exposure prophylaxis (PrEP).
Antiretroviral therapy may soon be obsolete, as scientists have successfully used immune cells to kick the dormant form of HIV out of its hiding place and destroy it. The findings may soon lead to an HIV vaccine.
Main Points:
PrEP works
HIV can be detected within weeks
Late testing can be lethal
Undetectable viral load can be an effective HIV prevention
Repeated exposures increase the risk of an activity
Not every HIV exposure leads to an infection
Rectal fluid can transmit HIV
People aren’t using condoms correctly
People with AIDS can have a near-normal life expectancy
Prepare for an aging HIV epidemic
______
Make sure to subscribe to get the latest episode.
Contact Us:
Pharmacy Benefit News: http://www.propharmaconsultants.com/pbn.html
Email: [email protected]
Website: http://www.propharmaconsultants.com/
Facebook: https://www.facebook.com/propharmainc
Twitter: https://twitter.com/ProPharma/
Instagram: https://www.instagram.com/propharmainc/
LinkedIn: https://www.linkedin.com/company/pro-pharma-pharmaceutical-consultants-inc/
Podcast: https://anchor.fm/pro-pharma-talks
